NDC Compounded Drug 26436-5352-5 Alprostadil; Papaverine Hydrobromide; Phentolamine Mesylate
Injection Intracavernous
Compounded Drug Product Information
NDC Crossover Products Matching Alprostadil; Papaverine Hydrobromide; Phentolamine Mesylate
NDC crossover of Trimix 10/30/2 with NDC 26436-5352 a human compounded drug with other similar products matching the same substance name (Alprostadil; Papaverine Hydrobromide; Phentolamine Mesylate) and the same administration route (intracavernous) or dosage form (injection).
NDC | Proprietary Name | Non-Proprietary Name | Package Desc | Dosage Form | Route Name | Company Name |
---|---|---|---|---|---|---|
26436-5037-5 | Trimix 10/30/1 | Trimix 10/30/1 | 5 mL in 1 SYRINGE, PLASTIC | Injection | Intracavernous | Hybrid Pharma |
26436-5282-1 | Trimix 8/23/0.8 | Trimix 8/23/0.8 | 5 mL in 1 SYRINGE, PLASTIC | Injection | Intracavernous | Hybrid Pharma |
26436-5555-1 | Trimix 10/7.5/0.2 | Trimix 10/7.5/0.2 | 5 mL in 1 SYRINGE, PLASTIC | Injection | Intracavernous | Hybrid Pharma |
Frequently Asked Questions
What is the NDC number assigned to Trimix 10/7.5/0.2?
Trimix 10/7.5/0.2 was assigned by its manufacturer with NDC product code 26436-5352. This product is a drug classified as a human compounded drug. Compounded drugs are medications created by combining or altering existing drugs to meet the specific needs of certain patients. The NDC directory only includes information about compounded drugs from facilities that choose to assign NDC numbers to their products.
Which are the NDC package codes for Trimix 10/7.5/0.2?
The NDC package code 26436-5352-5 was assigned to a 5 mL in 1 VIAL, GLASS of alprostadil; papaverine hydrobromide; phentolamine mesylate administered intracavernous via injection.
Who manufactures this product?
Trimix 10/7.5/0.2 is manufactured by an outsourced facility and labeled by Hybrid Pharma. All compounded drugs included in the NDC directory are classified as "Outsourcing Facility Compounded Human Drug Product (Exempt from Approval Requirements)". Outsourcing facilities are a type of drug compounding facility regulated under Section 503B of the FD&C Act could be eligible for exemptions from drug registration if they meet all the conditions specified under Section 503B.
Which are the NDC crossover matchings for this product?
We found 3 matching products that have the same substance, dosage form and administration route. The matching products are manufactured by Hybrid Pharma with NDC product codes 26436-5037-5, 26436-5282-1 and 26436-5555-1.